- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13:54 | H.C. Wainwright cuts Century Therapeutics target to $2 | 1 | Investing.com | ||
| 21.03. | Demystifying Century Therapeutics: Insights From 4 Analyst Reviews | 1 | Benzinga.com | ||
| 21.03. | Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating | 2 | Investing.com | ||
| 20.03. | Century Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics GAAP EPS of -$1.61 misses by $0.23, revenue of $6.59M beats by $3.24M | 2 | Seeking Alpha | ||
| 19.03. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 88 | GlobeNewswire (Europe) | Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated... ► Artikel lesen | |
| 28.02. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Century Therapeutics COO Farid Adrienne verkauft Aktien im Wert von 822 US-Dollar | 2 | Investing.com Deutsch | ||
| 22.01. | 4 Analysts Have This To Say About Century Therapeutics | 4 | Benzinga.com | ||
| 21.01. | Century Therapeutics startet Zelltherapie-Studie für Autoimmunerkrankungen | 2 | Investing.com Deutsch | ||
| 21.01. | Century Therapeutics launches cell therapy trial for autoimmune diseases | 1 | Investing.com | ||
| 21.01. | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 124 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen | |
| 13.01. | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.12.24 | Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler | 2 | MarketBeat | ||
| 13.12.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.11.24 | Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% | 2 | Benzinga.com | ||
| 06.11.24 | HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 | 4 | MarketBeat | ||
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 163 | GlobeNewswire (Europe) | - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,900 | -0,08 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,499 | +1,63 % | Palatin: Bremelanotide-Tirzepatide Combination Achieves Primary Endpoint In Phase 2 Obesity Study | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The... ► Artikel lesen | |
| BIOXXMED | 0,800 | +107,25 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| ORGANOVO | 2,140 | 0,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,597 | -6,14 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA ZSB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIRONA BIOCHEM CORP.... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,000 | -2,91 % | Viking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Time to Sell? | ||
| BIO-GATE | 0,760 | 0,00 % | Bio-Gate: Vielversprechende Wachstumschancen | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im Geschäftsjahr 2024 (per 31.12.) einen leichten Umsatzrückgang verbucht, besitzt aufgrund der innovativen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,682 | -2,57 % | War das der Trump Crash? Trotzdem steil aufwärts mit Evotec, Bayer, BioNTech, Defence Therapeutics oder Valneva? | Donald Trump bewegte die Börsen seit November 2024 steil nach oben - seine umstrittene neue Präsidentschaft wurde vor allem von den Börsianern gefeiert. Nun fühlt sich die Regentschaft etwas komisch... ► Artikel lesen | |
| VAXART | 0,347 | +6,17 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,280 | -0,71 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,059 | -0,67 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| GALAPAGOS NV | 21,800 | -3,71 % | Galapagos NV: Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting | Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders'... ► Artikel lesen | |
| AFFIMED | 0,930 | -100,00 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| IMMUNIC | 0,943 | -8,27 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen |
CENTURY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,024 (-5,19 %) liegt der Kurs bei 0,445 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.
